PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
29.15%
Revenue growth of 29.15% while 1475.HK is flat. Bruce Berkowitz would check if a small edge can widen further.
117.51%
Gross profit growth of 117.51% while 1475.HK is zero. Bruce Berkowitz would see if minimal improvements could expand further.
No Data
No Data available this quarter, please select a different quarter.
32.99%
Operating income growth of 32.99% while 1475.HK is zero. Bruce Berkowitz would see if this modest edge can become significant.
78.22%
Net income growth of 78.22% while 1475.HK is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
77.46%
EPS growth of 77.46% while 1475.HK is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
77.46%
Diluted EPS growth of 77.46% while 1475.HK is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.20%
OCF growth of 37.20% while 1475.HK is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
-4.08%
Negative FCF growth while 1475.HK is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-90.92%
Negative 10Y revenue/share CAGR while 1475.HK stands at 39.74%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
No Data
No Data available this quarter, please select a different quarter.
1895.74%
3Y revenue/share CAGR above 1.5x 1475.HK's 39.74%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-176.76%
Negative 10Y OCF/share CAGR while 1475.HK stands at 34.05%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
51.22%
3Y OCF/share CAGR above 1.5x 1475.HK's 34.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-34.38%
Negative 10Y net income/share CAGR while 1475.HK is at 65.50%. Joel Greenblatt sees a major red flag in long-term profit erosion.
No Data
No Data available this quarter, please select a different quarter.
-1383.05%
Negative 3Y CAGR while 1475.HK is 65.50%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.87%
Equity/share CAGR of 7.87% while 1475.HK is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while 1475.HK invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-99.62%
Firm’s AR is declining while 1475.HK shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-14.83%
Inventory is declining while 1475.HK stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.21%
Negative asset growth while 1475.HK invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.05%
We have a declining book value while 1475.HK shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-52.85%
We’re deleveraging while 1475.HK stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut SG&A while 1475.HK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.